{"nctId":"NCT01932970","briefTitle":"Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide","startDateStruct":{"date":"2013-08-12","type":"ACTUAL"},"conditions":["Hyperparathyroidism, Secondary"],"count":158,"armGroups":[{"label":"Etelcalcetide","type":"EXPERIMENTAL","interventionNames":["Drug: Etelcalcetide"]}],"interventions":[{"name":"Etelcalcetide","otherNames":["KAI 4169","AMG 416","Parsabiv™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Subject is 18 years of age or older at the time of informed consent.\n* Subject must be receiving maintenance hemodialysis 3 times weekly for at least 8 weeks.\n* Subject must have SHPT as defined by having a mean of 3 consecutive central laboratory screening predialysis serum parathyroid hormone (PTH) values ≥ 200 pg/mL, with measurements obtained from 3 different calendar weeks in the 4-week screening period while receiving cinacalcet.\n* Subject must have a mean of 3 consecutive central laboratory screening predialysis serum corrected calcium (cCa) values ≥ 7.5 mg/dL, with measurements obtained from 3 different calendar weeks in the 4-week screening period while receiving cinacalcet.\n* Subject must be on a stable dose of cinacalcet before screening (defined as no dose change within the 4 weeks prior to screening).\n* Other Inclusion Criteria may apply.\n\nExclusion Criteria\n\n* Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).\n* Subject has received AMG 416 in a prior clinical trial of AMG 416 (also known as KAI-4169).\n* Subject has known sensitivity to any of the products or components of AMG 416 to be administered during dosing.\n* Subject is unwilling to use effective contraception during the study, and for women, up to a period of up to 3 months after the last dose of AMG 416.\n* Subject is pregnant or nursing.\n* Anticipated or scheduled parathyroidectomy during the study period.\n* Subject has received a parathyroidectomy within 6 months prior to dosing.\n* Other Exclusion Criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Parathyroid Hormone During the Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Corrected Calcium < 8.3 mg/dL During the 4-week Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Symptomatic Hypocalcemia During the 4-week Treatment Period","description":"Hpocalcemia was used for events of decreased calcium accompanied by clinical signs and symptoms of hypocalcemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":148},"commonTop":[]}}}